The FDA has approved J&J's (JNJ) Invokana drug for treating type 2 diabetes in a new way by...

The FDA has approved J&J's (JNJ) Invokana drug for treating type 2 diabetes in a new way by causing the body to excrete blood sugar via the urine rather than affecting the supply or use of insulin. The agency said J&J must carry out five post-marketing studies to determine whether the drug increases the risks of strokes, heart attacks and other side effects. Invokana is forecast to generate sales of $667M by 2016.

From other sites
Comments (5)
  • Joe Springer
    , contributor
    Comments (2650) | Send Message
    Sweet pea
    Keeper of my soul
    I know sometimes I'm out of control
    You're the only reason I keep on coming
    You're the only reason I keep on coming yeah
    You're the only reason I keep on coming home

    31 Mar 2013, 04:16 AM Reply Like
  • blueump1
    , contributor
    Comments (2) | Send Message
    This great news for a lot people that have to take insulin. Blessing in happing.
    1 Apr 2013, 04:58 AM Reply Like
  • WFSimonsen
    , contributor
    Comment (1) | Send Message
    A novel treatment modality for a chronic illness that is becoming a pandemic.... what is not to like about the company's prospects going forward. (Of course, safety and efficacy testing after the drug is FDA approved for prescription use will be ongoing and may turn up some adverse events. But being the first to market has such a huge economic advantage that profits will likely create a cash cow large enough to offset any future liabilities.)
    1 Apr 2013, 04:59 AM Reply Like
  • Bidman
    , contributor
    Comments (10) | Send Message
    What about the plethora of lawsuits over the knee/hip replacements?
    1 Apr 2013, 05:31 AM Reply Like
  • bernie 1
    , contributor
    Comments (686) | Send Message
    Any improvement that medical science do for Diabetes has to be an improvement. My older brother who lives alone has passed out & ended up in the hospital 4 times in the last 2 years. As people with type 2 age it becomes so much more serious because of memory lapses. I surly hope JNJ or any of the other research firms find something soon.
    1 Apr 2013, 08:40 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs